Content on this page:
Content on this page:
Laboratory Tests and Ancillaries
The
lab tests performed for the diagnosis of SLE include a complete blood count (CBC),
urinalysis, liver and renal function tests, erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP), antinuclear antibodies (ANAs), anti-double
stranded deoxyribonucleic acid (anti-dsDNA), complement 3 and 4 (C4 and C4),
and antiphospholipid antibodies.
ANAs are
present in approximately 95% of patients with systemic lupus erythematosus. A
negative test indicates a low clinical probability of systemic lupus
erythematosus; a positive test alone has a poor diagnostic value without the
clinical features of autoimmune rheumatic disease.
The entry criterion in the diagnosis
of systemic lupus erythematosus is an ANA titer of ≥1:80 on HEp-2 cells or an
equivalent positive test is measured at least once. It is recommended to test by indirect immunofluorescence on HEp-2 cells or a
solid-phase ANA screening immunoassay with at least equivalent performance. If the patient is ANA negative, an alternative entry
criterion could be low complement levels and/or the presence of
antiphospholipid antibodies.
Specific Manifestations of Systemic
Lupus Erythematosus
Lupus
Nephritis
Patients suspected of having
lupus nephritis should immediately undergo a renal biopsy to confirm the
diagnosis, evaluate severity, and determine prognosis and therapy.
The
indications for renal biopsy in systemic lupus erythematosus patients include
an unexplained increase in serum creatinine in the absence of alternative
causes (eg sepsis, hypovolemia, medications) and confirmed proteinuria of ≥1
g/24 hr or reproducible proteinuria of ≥0.5 g/24 hr plus glomerular hematuria
and/or cellular casts.
Please see Lupus Nephritis disease
management chart for further information.
Neuropsychiatric SLE (NPSLE)
Diagnostic work-up may include lumbar puncture, nerve conduction studies
(NCS), neuropsychological assessment of cognitive function, cerebrospinal fluid
analysis, electroencephalography (EEG), and neuroimaging such as T1/T2 MRI,
diffusion-weighted imaging, or gadolinium-enhanced T1 sequences.